David Nierengarten, Ph.D., has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company, helps him succeed in analyzing both science and business models. In addition, David has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. David received his B.S. in Biochemistry from the University of Wisconsin-Madison, and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.
David’s Edge: His early state venture capital investing experience makes him well rounded, and can be found as a resource for M&A, and IPO trends for small/mid cap biotechs. With his primary focus being clinical trials in oncology, he understands the complexities of gene therapy, and can explain the risk/reward scenarios for developing-stage biotechnology companies. Combing both experiences provides him insights for corporate operations that have helped him generate value creation in this event-driven space.
Since our founding in 1955, Wedbush has been a leader in the financial services industry providing our clients, both private and institutional, with a wide range of securities brokerage, wealth management, and investment banking services; Headquartered in Los Angeles, California with 100 registered offices and nearly 900 colleagues, the firm focuses on client service and financial safety, innovation, and the utilization of advanced technology.
Follow us on LinkedIn, Twitter, and Facebook.
The background of this firm and investment professionals may be found on FINRA’s BrokerCheck
Wedbush Financial Advisors and Independent Contractors may only conduct business with the residents of the states and/or jurisdictions for which they are properly registered.
Wedbush is an affiliate of Qapital, a fintech company. Advisory services associated with Wedbush Next Powered by Qapital are provided by Qapital Invest, LLC (“Qapital Invest”) an SEC-registered investment advisor and affiliate of Wedbush. Sales representatives associated with Wedbush Securities Inc. may receive compensation for referrals to Qapital and/or Qapital Invest.
Securities and Investment Advisory services are offered through Wedbush Securities, Inc. Member NYSE/FINRA/SIPC.
Third party entities named are not associated with Wedbush Securities.
Investment professionals may only conduct business and provide recommendations with residents of the states for which they are properly licensed. You can check the registration and background of an investment professional and their firm.
Please refer to FINRA’s BrokerCheck website for this information: FINRA’s BrokerCheck.
Fixed income securities are subject to increased loss of principal during periods of rising interest rates and are subject to various other risks including changes in credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications, and other factors. Investors should consider carefully information contained in the prospectus, including investment objectives, risks, charges, and expenses. You can request a prospectus by contacting your Wedbush Financial Advisor and/or Registered Representative. Past performance is never a guarantee of future returns.
BrokerCheck is a trusted tool that shows you employment history, certifications, licenses, and any violations for brokers and investment advisors.
